Author: user
incTANK Ventures Selected as Member of ARPA-H Investor Catalyst Hub Network
incTANK Ventures Joins a Nationwide Network Working to Accelerate Transformative Health Solutions
Cambridge, MA, December 10, 2024 – incTANK Ventures, an early stage investment company, announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.
incTANK Ventures is focused on university-sourced biotech startups in the Boston area,” noted Karl Ruping, Senior Managing Partner. “We have grown along with the regional ecosystem, leveraging government grant mechanisms, academic innovation, and industry partnerships. The incTANK team is excited to join the expanding ARPA-H Investor Catalyst Hub to advance the innovation network for patient needs.
incTANK Ventures joins a dynamic nationwide network of organizations aligned to ARPA-H’s overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.
Our spoke network embodies a rich and representative range of perspectives and expertise,” said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. “Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation.
As an Investor Catalyst Hub spoke, incTANK Ventures gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.
The spoke network will continue to grow as the Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis. Interested organizations can visit https://investorcatalysthub.org/ to learn more or submit a membership application.
About incTANK Ventures
incTANK Ventures is an early stage investor group focused on university-sourced biotech startups with talented founders, core intellectual property assets, and global market opportunities. We work with leading research institutes and cutting-edge investigators with deep domain expertise to build exciting ventures that provide novel solutions for patient needs. The incTANK team is comprised of experienced founders, industry leaders, and international investors who have assembled a portfolio of successful ventures spanning medical devices, connected health and computational drug design. Visit us at www.inctank.com.
For more, see the incTANK press release.
BARDA Partners with Tiba Biotech to Develop Influenza Therapeutics
Tiba Biotech announced its new partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), through initiation of an EZ-BAA contract to develop groundbreaking therapeutics against influenza.
We are excited to receive this BARDA award, which will advance Tiba’s innovative approach to combating influenza and other viral threats. We believe our technology has the potential to transform the landscape of RNA therapeutics..
— Jusdave Chahal, co-founder and lead investigator of the project
For more, see the Tiba Biotech press release.
Elemental Machines Announces Edward Seguine As New Chief Executive
Elemental Machines, the pioneering developer of the comprehensive Intelligent Operations Platform for life sciences, has appointed Ed Seguine as Chief Executive Officer. Sridhar Iyengar, PhD, founder and incumbent CEO, will remain actively involved day-to-day as Chief Innovation Officer, leading the development of new products and solutions to address highly complex customer needs. Iyengar will also serve as the Chairman of the Board.
Ed’s leadership and experience are exactly what Elemental Machines needs to scale our innovative technology platform to the next level,” said Iyengar. “I’m eager to partner with him to accelerate our success with over 500 current clients to scale the organization, expand our capabilities, and safeguard our customers’ mission-critical data.
— Sridhar Iyengar, Elemental Machines CIO
For more, see the Elemental Machines press release.
Agrivida selected to Real Leaders list of 200 Top Impact Companies of 2022
Real Leaders announced the newly selected winners of its 2022 Top Impact Companies from around the world. This year the magazine recognizes the addition of Agrivida, a team of leading experts in biochemistry, plant biology, molecular biology, agriculture, and nutrition. “Business leaders across the globe are rapidly discovering that to be competitive – and to grow and thrive – they must forgo shortsighted thinking in favor of a farsighted vision that takes into account their company’s social and environmental impact,” said Mark Van Ness, Founder of Real Leaders. “We are excited to welcome new and old companies alike to the impact movement, and into the Real Leaders Impact Awards community.”
For the underlying news item see the Real Leaders announcement.
Elemental Machines Acquires TetraScience Lab Monitoring
Elemental Machines, a manufacturer of universal laboratory asset management technology for research, clinical, and testing labs around the world, announced its successful acquisition of the Tetra Lab Monitoring business from Boston-based TetraScience. The acquisition comes on the heels of a landmark year for Elemental Machines, which recently unveiled groundbreaking asset scheduling and utilization monitoring solutions, and nearly doubled the number of labs served by its universal LabOps platform.
Purchase of key TetraScience Lab Monitoring business hardware, talent, and novel asset integrations creates a clear leader in the eBy bringing Tetra Lab Monitoring under the Elemental Machines roof, we’re doubling down on our commitment to the acceleration of science. The addition of the Tetra Lab Monitoring team and technology will be invaluable as we continue our growth in service of the LabOps community.merging field of LabOps.
— Sridhar Iyengar, Elemental Machines CEO
For more, see the Elemental Machines press release.
A Shot in the Arm with 3D Printed Microneedle Patch
Public health officials are looking for innovative solutions to vaccine delivery in the face of the continuing COVID-19 pandemic and ongoing supply chain shortages. Recently highlighted in a new article, a group of scientists and engineers are working together to develop a novel intradermal delivery device.
Tiba’s collaboration with the University of Pittsburg and Carnegie Mellon University is centered on a new 3-D printed micro array patch for mRNA vaccine delivery. Microneedle arrays comprise hundreds of tiny needles on a miniature patch that, when applied to the skin, quickly dissolve and deliver the mRNA nanoparticles. In addition to overcoming the general aversion to traditional needles, these devices do not require the same level of cold-chain storage and can allow for 1/100th of the dose of a traditional vaccine to be delivered.
For the underlying article see A Shot in the Arm with 3D Printed Microneedle Patch.
Agrivida Announces USDA Deregulation of GRAINZYME Phytase Feed Enzyme
Agrivida, a privately held biotechnology company, announces the deregulation of its innovative GRAINZYME® Phytase enzyme feed additive by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA’s APHIS). Deregulation is effective as of September 21, 2021.
Continue ReadingTiba joins in the CIVIC effort to develop a universal influenza vaccine
Tiba Biotech announces the funding of an mRNA-based universal influenza vaccine project with support from the National Institute of Allergy and Infectious Diseases (NIAID) and its Collaborative Influenza Vaccine Innovation Centers (CIVIC) initiative. This moves forward Tiba’s earlier universal influenza collaboration with Prof. Florian Krammer of the Icahn School of Medicine at Mount Sinai.
For more, see the Tiba news post.
Revela Bio completes final phase of NIH contract to develop PET imaging panel.
Revela completed the final phase of an NIH contract for the non-invasive detection of human CD8+ T cells: A PET-based approach to assess the human immune system. Current methods to predict responses to immunotherapy are inadequate. Revela has shown that tracking the short-term infiltration of CD8+ T cells into a tumor can predict longer-term responses to immunotherapy, and therefore has the potential to help clinicians more accurately tailor treatment plans. The overall goal of this contract was the successful preclinical development of a product for in vivo tracking of intratumoral human CD8+ T cells using PET imaging. A panel of novel VHHs targeting human CD8 protein have been developed and are entering late-stage preclinical development over the coming year..
For more, see the Revela website.
Tiba secures NIAID grant for an RNA-based multi-antigen vaccine for SARS-CoV-2
Tiba Biotech was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
The proposal is to develop an RNA-based multi-antigen SARS-CoV-2 vaccine, supporting NIAID’s call to develop a vaccine using emerging antigen design strategies and novel delivery approaches. The SARS-CoV-2 pandemic is actively threatening public health, world economies, and ways of life. Vaccine candidates are in human trials now, but long-term solutions will require an adaptable vaccine system that can be universalized broadly to all members of the coronavirus family.
For more, see the Tiba news post.
Recent Comments